.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,329,402

« Back to Dashboard

Details for Patent: 7,329,402

Title:Methods of imaging and treatment
Abstract: Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning may comprise exposing the patient to a first type of ultrasound energy and then interrogating the patient using a second type of ultrasound energy. The targeting ligand preferably targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The methods may be used to detect a thrombus, enhancement of an old or echogenic thrombus, low concentrations of vesicles and vesicles targeted to tissues, cells or receptors.
Inventor(s): Unger; Evan C. (Tucson, AZ), Wu; Yunqiu (Tucson, AZ)
Assignee: Imarx Pharmaceutical Corp. (Tucson, AZ)
Filing Date:Jan 13, 2003
Application Number:10/341,167
Claims:1. A therapeutic ultrasound method comprising: (i) administering to a patient a vesicle composition which comprises vesicles comprising a lipid encapsulating a gas; optionally in combination with a targeting ligand; and (ii) exposing said patient to a first ultrasound energy having a first insonation frequency, wherein the exposure to the first insonication frequeney causes the vesicles to oscillate; and (iii) subsequently exposing the patient to a second ultrasound energy having a second insonation frequency, wherein the first insonation frequency is different from the second insonation frequency, and wherein the exposure to the second insonication frequency is conducted while the vesicles are oscillating.

2. A method according to claim 1, wherein said oscillation of vesicles causes thrombolysis.

3. A method according to claim 1, wherein said vesicles further comprise a bioactive agent which is released upon application of said ultrasound.

4. A method according to claim 1, wherein said first and second insonation frequencies each have a bandwidth of about 100 kHz or less.

5. A method according to claim 4, wherein said bandwidth is about 50 kHz or less.

6. A method according to claim 1, further comprising detecting the reflected ultrasound signal.

7. A method according to claim 6, wherein said method comprises the use of a broadband receiver and a digital filter with multiple center frequencies, wherein said center frequencies are digitally adjusted with respect to an insonating frequency, and filter gates and bandwidth windows are selected and controlled such that said filter rejects signals with center frequencies outside of a selected range.

8. A method according to claim 1, wherein said first and second ultrasound energies are administered by pulsing and phase modulation.

9. A method according to claim 1, wherein the frequency of said first ultrasound energy is lower than the frequency of said second ultrasound energy.

10. A method according to claim 9, wherein said first ultrasound energy has a frequency of about 1 MHz and said second ultrasound energy has a frequency of about 3 MHz.

11. A method according to claim 9, wherein said second ultrasound energy has a frequency at least two times that of said first ultrasound energy.

12. A method according to claim 9, wherein said first ultrasound energy has a frequency of about 100 kHz and said second ultrasound energy has a frequency of about 3 MHz.

13. A method according to claim 9, wherein said first ultrasound energy has a frequency of about 20 kHz and said second ultrasound energy has a frequency of about 1 MHz.

14. A method according to claim 9, wherein said first ultrasound energy is administered as a pulse train.

15. A method according to claim 14, wherein said pulse train comprises from about 8 to about 20 pulses.

16. A method according to claim 14, wherein said pulse train comprises about 10 or fewer pulses.

17. A method according to claim 9, wherein said first ultrasound energy is administered as a single pulse of low frequency ultrasound, and said second ultrasound energy comprises pulses of higher frequency sound.

18. A method according to claim 9, wherein said first ultrasound energy is a single pulse of about 100 kHz, said second ultrasound energy comprises one or several pulses of higher frequency ultrasound, and said second ultrasound energy is applied within about 40 milliseconds of said first ultrasound energy.

19. A method according to claim 1, wherein said application of ultrasound comprises forming a summation of several pulses given in rapid succession after an initial stimulation pulse.

20. A method according to claim 1, wherein said first and second ultrasound energies comprise pulses that are phase modulated or delayed with respect to each other.

21. A method according to claim 20, wherein said phase modulation and/or time delay pulses cause vesicle oscillation and collapse.

22. A method according to claim 20, wherein said first ultrasound energy comprises one pulse or a pulse train with a duration from about 10 microseconds to about 10 seconds.

23. A method according to claim 22, wherein said duration is from about 1 millisecond to about 2 seconds.

24. A method according to claim 19, wherein a peak acoustic pressure for a first pulse of about 100 pascals to about 10 megapascals is employed.

25. A method according to claim 24, wherein said peak acoustic pressure is about 1 kilopascal to about 5 megapascals.

26. A method according to claim 25, wherein said peak acoustic pressure is about 10 kilopascals to about 5 megapascals.

27. A method according to claim 1 wherein said vesicles comprise lipid vesicles.

28. A method according to claim 27 wherein said lipid vesicles are selected from the group consisting of micelles and liposomes.

29. A method according to claim 27 wherein said lipid comprises a phospholipid.

30. A method according to claim 29 wherein said phospholipid is selected from the group consisting of phosphatidyicholine, phosphatidylethanolamine and phosphatidic acid.

31. A method according to claim 30 wherein said phosphatidyicholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.

32. A method according to claim 31 wherein said phosphatidyicholine comprises dipalmitoylphosphatidylcholine.

33. A method according to claim 30 wherein said phosphatidylethanolamine is selected from the group consisting of dipalmitoyl-phosphatidylethanolamine, dioleoylphosphatidylethanolamine, N-succinyldioleoyl-phosphatidylethanolamine and 1-hexadecyl-2-palmitoylglycerophosphoethanolamine.

34. A method according to claim 33 wherein said phosphatidylethanolamine comprises dipalmitoylphosphatidylethanolamine.

35. A method according to claim 30 wherein said phosphatidic acid comprises dipalmitoylphosphatidic acid.

36. A method according to claim 27 wherein said lipid further comprises a polymer.

37. A method according to claim 36 wherein said polymer comprises a hydrophilic polymer.

38. A method according to claim 37 wherein said polymer comprises polyethylene glycol.

39. A method according to claim 1 wherein said gas has limited solubility.

40. A method according to claim 1 wherein said gas comprises a fluorinated gas.

41. A method according to claim 40 wherein said fluorinated gas comprises a perfluorocarbon.

42. A method according to claim 41 wherein said perfluorocarbon gas is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane and perfluorocyclobutane.

43. A method according to claim 42 wherein said perfluorocarbon gas is selected from the group consisting of perfluoropropane and perfluorobutane.

44. A method according to claim 43 wherein said perfluorocarbon gas comprises perfluorobutane.

45. A method according to claim 1 wherein said gas is derived, at least in part, from a gaseous precursor.

46. A method according to claim 45 wherein said gaseous precursor has a boiling point of greater than about 37.degree. C.

47. A method. according to claim 45 wherein said gaseous precursor comprises a perfluorocarbon.

48. A method according to claim 47 wherein said perfluorocarbon is selected from the group consisting of perfluoropentane and perfluorohexane.

49. A method according to claim 1 wherein said targeting ligand targets cells or receptors selected from the group consisting of myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor.

50. A method according to claim 49 wherein said targeting ligand is selected from the group consisting of proteins, peptides, saccharides, steroids, steroid analogs, bioactive agents and genetic material.

51. A method according to claim 50 wherein said targeting ligand is selected from the group consisting of proteins, peptides and saccharides.

52. A method according to claim 51 wherein said targeting ligand is selected from the group consisting of proteins and peptides.

53. A method according to claim 52 wherein said targeting ligand comprises a peptide.

54. A method according to claim 53 wherein said peptide comprises a sequence selected from the group consisting of Arg-Gly-Asp and Lys-Gln-Ala-Gly-Asp-Val.

55. A method according to claim 1 wherein said targeting ligand is associated with said lipid, protein or polymer covalently.

56. A method according to claim 1 wherein said targeting ligand is associated with said lipid, protein or polymer non-covalently.

57. A method according to claim 55 wherein said covalent association comprises a covalent bond selected from the group consisting of amide, thioamide, ether, ester, thioester, --O--, --S--, --S.sub.n--, where n is greater than 1, carbamate, --NH--, --NR--, where R is alkyl of from 1 to about 4 carbons, urethane, and substituted imidate bonds.

58. A method according to claim 57 wherein said covalent association further comprises crosslinking.

59. A method according to claim 55 wherein said targeting ligand is covalently associated with said lipid, protein or polymer via a linking group.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc